S.252

An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration

Sponsors: Sen. Virginia Lyons

Last Recorded Action: 9/11/2020 - Recommitted to Committee on Health and Welfare on motion of Senator Ashe

Committee Activity - Meeting Full List

Regular Session 2019-2020

Friday, January 17, 2020

Committee(s):

Senate Committee on Health and Welfare

-

S.252 - An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration

Walk-through

Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel

Tuesday, February 4, 2020

Committee(s):

Senate Committee on Health and Welfare

10:45 AM

S.252 - An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration

Walk-through

Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel

Friday, February 14, 2020

Committee(s):

Senate Committee on Health and Welfare

9:00 AM

S.252 - An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration

Daniel Weiss, Professor of Medicine, Professor of Cell and Molecular Biology, University of Vermont
Cindy Bruzzese, Director, Vermont Ethics Network
Jessa Barnard, Executive Director, Vermont Medical Society
Lauren Hibbert, Director, Office of Professional Regulation, Office of the Secretary of State
Charity Clark, Chief of Staff, Attorney General's Office
Shayla Livingston, Public Health Policy Advisor, Department of Health
Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel

Tuesday, February 18, 2020

Committee(s):

Senate Committee on Health and Welfare

10:30 AM

S.252 - An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration

Mark-up

Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel
Cindy Bruzzese, Director, Vermont Ethics Network
Lauren Hibbert, Director, Office of Professional Regulation, Office of the Secretary of State
David Herlihy, Director of Hospital Licensing, Department of Health, Executive Director, Vermont Board of Medical Practice

Tuesday, February 25, 2020

Committee(s):

Senate Committee on Health and Welfare

10:30 AM

S.252 - An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration

Discussion

Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel

Friday, February 28, 2020

Committee(s):

Senate Committee on Health and Welfare

10:00 AM

S.252 - An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration

Discussion and possible vote

Jonathon Fenton, Vermont Regenerative Medicine
Charity Clark, Chief of Staff, Attorney General's Office
Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel
Jessa Barnard, Executive Director, Vermont Medical Society

11:15 AM

S.252 - An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration

Discussion

Tuesday, March 10, 2020

Committee(s):

Senate Committee on Health and Welfare

-

S.252 - An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration

Discussion and possible vote

Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel
David Herlihy, Director of Hospital Licensing, Department of Health, Executive Director, Vermont Board of Medical Practice

Friday, March 13, 2020

Committee(s):

Senate Committee on Health and Welfare

8:50 AM

S.252 - An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration

Discussion

Thursday, August 27, 2020

Committee(s):

Senate Committee on Health and Welfare

11:20 AM

S.252 - An act relating to stem cell therapies not approved by the U.S. Food and Drug Administration

Walk through, committee discussion

Jennifer Carbee, Deputy Chief Counsel, Office of Legislative Counsel